Results 201 to 210 of about 430,909 (261)

The OASIS Consortium: integrating multi-omics technologies to transform chemical safety assessment. [PDF]

Toxicol Sci
Rouquié D, Bender A, Cheah J, Crute CE, Dalmas D, Ewald J, Fullerton A, Harrill JA, Kadri S, Kleinstreuer N, Kramer N, LaRocca J, Mitchell CA, Seal S, Singh S, Carpenter AE.   +15 more
europepmc   +1 more source

Von Economo Neuron Loss in Frontotemporal Dementia: A Meta‐Analysis of Neuropathological Studies

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Von Economo neurons (VENs) have been reported to be vulnerable to neurodegeneration in frontotemporal dementia (FTD), particularly the behavioral variant (bvFTD), but these findings have not been systematically assessed across independent brain banks.
Daniel Talmasov, Alexander F. Santillo, Patrick R. Hof   +2 more
wiley   +1 more source

Rational Design of Novel Inhibitors: Integrating 3D-QSAR and Molecular Dynamics. [PDF]

Biomed Res Int
Shakour N, Fayyaz A, Hadizadeh F, Sepehri S.   +3 more
europepmc   +1 more source

A Systematic Comparison of Alpha‐Synuclein Seed Amplification Assays for Increasing Reproducibility

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Seed amplification assays (SAAs) enable ultrasensitive detection of misfolded α‐synuclein across biofluids and tissues. Yet, heterogeneity in protocols limits cross‐study comparability and clinical translation. Here, we review α‐synuclein SAA methods and their performance across various biological matrices.
Manuela Amaral‐do‐Nascimento, Daniela F. Santos, Tuane C. R. G. Vieira, Tiago F. Outeiro   +3 more
wiley   +1 more source

Editorial: Biomarkers of response to interventions in psychiatry. [PDF]

Front Psychiatry
Franco SB, Pacheco-Barrios K, Uchida RR, Marques LM.   +3 more
europepmc   +1 more source

Prognostic Value of Neurofilament Light Chain and Glial Fibrillary Acidic Protein in ALD‐Related Myelopathy

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background X‐linked adrenoleukodystrophy (X‐ALD) is a neurometabolic disorder caused by pathogenic variants in ABCD1, leading to slowly progressive spinal cord disease in nearly all affected men. Sensitive biomarkers to quantify disease severity and predict progression are needed for clinical care and trial design.
Eda G. Kabak, Marije M. C. Voermans, Hans Heijst, Charlotte E. Teunissen, Marc Engelen   +4 more
wiley   +1 more source

Unifying pharmacology, systems biology, and regenerative medicine to advance personalized therapies. [PDF]

Front Pharmacol
Martins A.
europepmc   +1 more source

Ofatumumab in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease: A Comparison With Rituximab

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate the efficacy and safety of ofatumumab in patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), and compare it with rituximab. Methods We conducted a single–center, observational study including 22 MOGAD patients treated with ofatumumab and 21 treated with rituximab.
Yuxin Fan, Lei Zhou, Jingzi ZhangBao, Hongmei Tan, Zhouzhou Wang, Chao Quan   +5 more
wiley   +1 more source

Mechanistic Insights into Protein Corona Formation: The Surface Charge of Mesoporous Silica Nanoparticles Determines the Orientation and the Conformation of Adsorbed BSA Protein. [PDF]

Langmuir
Ballicu A, Meloni GM, Farci M, Tocco D, Piludu M, Parsons DF, Carucci C, Jachimska B, Salis A.   +8 more
europepmc   +1 more source